Background/aims: The impact of pegylated-interferon (PEG-IFN) α-2b on liver regeneration has not yet been elucidated.

Methodology: Rats were divided into the following four groups: 70% hepatectomy (Hx); 70% Hx+PEG-IFN; 90% Hx and 90% Hx+PEG-IFN group (n=6 each). Rats were pretreated with subcutaneous of PEGIFN α-2b (1.5 μg/kg) administration 24 hours before Hx. Samples were taken 24, 48 and 72 hours after Hx and the following parameters were investigated: blood analysis (AST, WBC, PLT); liver weight to body weight ratio (Lw/Bw ratio); survival and PCNA labeling index (LI).

Results: In the 90% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group in blood analysis; AST after postoperative 24 hours (2511 vs. 2466 IU/L), WBC (1200 vs. 1290) and PLT (107 vs. 111 x 10⁴/mm³), in Lw/Bw ratio at postoperative 0, 24, 48, 72 hours, respectively (0.38, 0.60, 1.14, 1.69 vs. 0.37, 0.64, 1.12, 1.63), in postoperative survival (40% vs. 45%), and in PCNA LI at postoperative 0, 24, 48, 72 hours, respectively (10.4%, 16.8%, 14.6%, 12.8% vs. 10.0%, 17.1%, 15.6%, 13.7%). In the 70% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group for all parameters.

Conclusions: Our data demonstrated that PEG-IFN α-2b did not affect liver regeneration and the early use of PEG-IFN α-2b would cause no problems after liver transplantation using partial grafts including living donor liver transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.5754/hge10401DOI Listing

Publication Analysis

Top Keywords

peg-ifn α-2b
12
hx+peg-ifn group
12
postoperative hours
12
impact pegylated-interferon
8
liver regeneration
8
blood analysis
8
analysis ast
8
lw/bw ratio
8
model difference
8
difference hx+peg-ifn
8

Similar Publications

Background: Pegylated interferon- (PEG-IFN-α) therapy could decrease hepatitis B surface antigen (HBsAg) and improve long-term prognosis of hepatitis B virus (HBV) infection. However, studies on safety and efficacy of PEG-IFN- for patients with HBV-related cirrhosis are limited.

Methods: This was a single-center study.

View Article and Find Full Text PDF

Background: The long-term stability of hepatitis B surface antigen (HBsAg) seroclearance following peginterferon alpha (peg-IFN-α)-based therapy has not been extensively studied, leaving the full potential and limitations of this strategy unclear.

Aim: To assess HBsAg recurrence after seroclearance achieved by peg-IFN-α regimens.

Methods: This prospective, multicenter, observational study was conducted from November 2015 to June 2021 at three Chinese hospitals: The Second Affiliated Hospital of Xi'an Jiaotong University, Ankang Central Hospital, and The Affiliated Hospital of Yan'an University.

View Article and Find Full Text PDF
Article Synopsis
  • * Current treatments, primarily pegylated interferon (PEG-IFN), can suppress HDV but have low cure rates and significant side effects, making their use challenging.
  • * New antiviral therapies are being developed that target different stages of HDV replication, showing potential for better long-term treatment results when used alongside PEG-IFN.
View Article and Find Full Text PDF

Objective: This meta-analysis aims to assess the efficacy and safety of adding pegylated interferon (Peg-IFN) to long-term nucleos(t)ide analogs (NAs) treatment for achieving functional cure in patients with chronic hepatitis B (CHB).

Methods: This meta-analysis was registered in PROSPERO (CRD42024519116). We searched PubMed, Embase, Cochrane Library and Web of Science for randomized controlled trials that compared adding Peg-IFN to long-term NAs with NAs alone for the treatment of CHB.

View Article and Find Full Text PDF
Article Synopsis
  • A study involving 80 patients with chronic hepatitis B (CHB) found that 15% experienced virologic breakthrough (VBT) after switching from nucleos(t)ide analogue (NA) therapy to pegylated interferon alpha (Peg-IFN-α) treatment.
  • Patients who had higher levels of HBcrAg (≥5 logU/mL) and HBsAg (≥100 IU/mL) showed a significantly increased risk of VBT and were less likely to achieve HBsAg clearance post-therapy.
  • The research indicates that monitoring HBcrAg and HBsAg levels can provide insights into immune responses and help prevent VBT, potentially improving the chances of achieving a functional cure for CH
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!